Stock Analysis
- South Korea
- /
- Medical Equipment
- /
- KOSDAQ:A338220
3 KRX Growth Stocks With High Insider Ownership To Watch
Reviewed by Simply Wall St
The South Korean market has been flat in the last week, with the Financials sector down 3.1%. Despite this, earnings are expected to grow by 29% per annum over the next few years, making it crucial to identify growth companies with high insider ownership as they often signal strong confidence from those closest to the business.
Top 10 Growth Companies With High Insider Ownership In South Korea
Name | Insider Ownership | Earnings Growth |
People & Technology (KOSDAQ:A137400) | 16.5% | 35.6% |
Seojin SystemLtd (KOSDAQ:A178320) | 30.6% | 52.1% |
Bioneer (KOSDAQ:A064550) | 17.5% | 97.6% |
ALTEOGEN (KOSDAQ:A196170) | 26.6% | 99.5% |
Oscotec (KOSDAQ:A039200) | 26.3% | 122% |
Vuno (KOSDAQ:A338220) | 19.5% | 110.9% |
Park Systems (KOSDAQ:A140860) | 33% | 35.6% |
HANA Micron (KOSDAQ:A067310) | 21.3% | 106.2% |
UTI (KOSDAQ:A179900) | 33.1% | 134.6% |
Techwing (KOSDAQ:A089030) | 18.7% | 83.6% |
Let's take a closer look at a couple of our picks from the screened companies.
ALTEOGEN (KOSDAQ:A196170)
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩17.11 trillion.
Operations: The company's revenue segment is primarily derived from its biotechnology division, which generated ₩90.79 billion.
Insider Ownership: 26.6%
Earnings Growth Forecast: 99.5% p.a.
ALTEOGEN Inc. has recently received MFDS approval for Tergase®, a high-purity recombinant hyaluronidase, marking its transition to a commercial-stage company. The firm's revenue is forecasted to grow 64.2% annually, significantly outpacing the market average of 10.8%. Earnings are expected to rise by 99.46% per year, with profitability anticipated within three years and a very high return on equity projected at 66.3%. However, shareholders have faced dilution over the past year and share price volatility remains high.
- Unlock comprehensive insights into our analysis of ALTEOGEN stock in this growth report.
- In light of our recent valuation report, it seems possible that ALTEOGEN is trading beyond its estimated value.
Vuno (KOSDAQ:A338220)
Simply Wall St Growth Rating: ★★★★★★
Overview: Vuno Inc. is a company that develops medical artificial intelligence solutions and has a market cap of ₩474.28 billion.
Operations: Vuno Inc. generates revenue primarily from the production of artificial intelligence medical software, amounting to ₩20.42 billion.
Insider Ownership: 19.5%
Earnings Growth Forecast: 110.9% p.a.
Vuno's earnings are forecast to grow 110.92% annually, with revenue expected to increase by 41% per year, significantly outpacing the market average of 10.8%. The company is projected to become profitable within three years and achieve a very high return on equity of 107.2%. However, shareholders have experienced dilution over the past year and the share price has been highly volatile in recent months.
- Get an in-depth perspective on Vuno's performance by reading our analyst estimates report here.
- Our expertly prepared valuation report Vuno implies its share price may be too high.
Enchem (KOSDAQ:A348370)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Enchem Co., Ltd. manufactures and sells electrolytes and additives for secondary batteries and EDLC, with a market cap of ₩4.46 billion.
Operations: Revenue from electronic components and parts for Enchem Co., Ltd. amounts to ₩348.75 million.
Insider Ownership: 19.4%
Earnings Growth Forecast: 155.2% p.a.
Enchem's revenue is forecast to grow 63% annually, significantly outpacing the South Korean market average of 10.8%. Earnings are expected to increase by 155.2% per year, with profitability anticipated within three years. However, shareholders have faced dilution over the past year and the share price has been highly volatile recently. No substantial insider trading activity has been reported in the last three months.
- Navigate through the intricacies of Enchem with our comprehensive analyst estimates report here.
- Upon reviewing our latest valuation report, Enchem's share price might be too optimistic.
Turning Ideas Into Actions
- Reveal the 86 hidden gems among our Fast Growing KRX Companies With High Insider Ownership screener with a single click here.
- Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSDAQ:A338220
Vuno
Operates as a medical artificial intelligence (AI) solution development company.